CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Discover why CVS' turnaround may be underway with improved medical cost trends, segment growth, and raised FY2025 guidance.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

CVS will exit Obamacare plans in 2026, affecting 1 million members across 17 states, and close stores amid pharmacy desert ...

CVS Health’s insurance division Aetna will stop offering plans for individuals on the Affordable Care Act exchanges in 2026, after the company projected big losses in the business this year.

Four states have joined a federal whistleblower lawsuit against CVS Pharmacy, alleging the company of overbilling state Medicaid programs for prescription drugs. Attorneys general from ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Boosted by Microsoft's offerings, CVS intends to accelerate ... Expanding digital means CVS plans to improve its omnichannel pharmacy capabilities using Microsoft tools to provide personalised ...